VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Overview of attention for article published in Immunobiology, July 2025

Altmetric Badge

Mentioned by

twitter: 1 X user

bluesky: 1 Bluesky user

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 1 Bluesky users, with an upper bound of 118 followers.

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN scientiasalut.gencat.cat/handle/11351... #ScientiaVH

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN www.sciencedirect.com/science/arti... #hvhebron #nefroped [Text …

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.